| __timestamp | Takeda Pharmaceutical Company Limited | Viatris Inc. |
|---|---|---|
| Wednesday, January 1, 2014 | 382096000000 | 581800000 |
| Thursday, January 1, 2015 | 345927000000 | 671900000 |
| Friday, January 1, 2016 | 312303000000 | 876700000 |
| Sunday, January 1, 2017 | 325441000000 | 857900000 |
| Monday, January 1, 2018 | 368298000000 | 822200000 |
| Tuesday, January 1, 2019 | 492381000000 | 778200000 |
| Wednesday, January 1, 2020 | 455833000000 | 512600000 |
| Friday, January 1, 2021 | 526087000000 | 681000000 |
| Saturday, January 1, 2022 | 633325000000 | 662200000 |
| Sunday, January 1, 2023 | 729924000000 | 910700000 |
| Monday, January 1, 2024 | 729924000000 |
Unleashing the power of data
In the ever-evolving pharmaceutical landscape, research and development (R&D) investments are pivotal for innovation and growth. Over the past decade, Takeda Pharmaceutical Company Limited has consistently outpaced Viatris Inc. in R&D spending. From 2014 to 2023, Takeda's R&D expenses surged by approximately 91%, peaking in 2023. In contrast, Viatris's R&D investment remained relatively stable, with a modest increase of around 56% over the same period.
Takeda's aggressive R&D strategy reflects its commitment to pioneering new treatments and expanding its global footprint. The company's investment in R&D has grown from 38% of its 2014 levels to a staggering 73% by 2023.
Viatris, formed in 2020, has maintained a steady R&D investment, focusing on optimizing its existing portfolio. Despite missing data for 2024, the trend suggests a consistent approach to innovation.
Analyzing R&D Budgets: Zoetis Inc. vs Takeda Pharmaceutical Company Limited
R&D Spending Showdown: Takeda Pharmaceutical Company Limited vs United Therapeutics Corporation
R&D Insights: How Takeda Pharmaceutical Company Limited and Exelixis, Inc. Allocate Funds
Research and Development Expenses Breakdown: Takeda Pharmaceutical Company Limited vs Iovance Biotherapeutics, Inc.
Takeda Pharmaceutical Company Limited vs Ligand Pharmaceuticals Incorporated: Strategic Focus on R&D Spending
Takeda Pharmaceutical Company Limited or Taro Pharmaceutical Industries Ltd.: Who Invests More in Innovation?
Research and Development Investment: Takeda Pharmaceutical Company Limited vs BioCryst Pharmaceuticals, Inc.
Comparing Innovation Spending: Alnylam Pharmaceuticals, Inc. and Viatris Inc.
Analyzing R&D Budgets: Viatris Inc. vs Rhythm Pharmaceuticals, Inc.
R&D Spending Showdown: Viatris Inc. vs Amneal Pharmaceuticals, Inc.
Research and Development Expenses Breakdown: Viatris Inc. vs Arrowhead Pharmaceuticals, Inc.
Comparing Innovation Spending: Viatris Inc. and Celldex Therapeutics, Inc.